Physician profile
Yashasvi Chugh
NPI 1144635053
$42,796.99
in general payments reported to CMS, 2019-2025
23 companies · $5,816 in 2025
The $5,816 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.73 · 2020: $1,245 · 2021: $24K · 2022: $664 · 2023: $4,556 · 2024: $6,509 · 2025: $5,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $5,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,769.26 |
| Travel and Lodging | $5,110.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $24,420.46 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Symplicity G3 |
| Edwards Lifesciences Corporation | $8,663.91 | 2021-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Abbott Laboratories | $3,210.99 | 2022-2025 | Triclip, Mitraclip, Amplatzer Amulet |
| Ancora Heart, INC. | $2,944.97 | 2023-2025 | Accucinch, Accucinch |
| Boston Scientific Corporation | $1,603.66 | 2020-2025 | Mamba, Avvigo Guidance System, Watchman |
| Shockwave Medical, INC | $505.22 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Novartis Pharmaceuticals Corporation | $322.22 | 2023-2025 | |
| W. L. Gore & Associates, INC. | $178.04 | 2024-2025 | Gore Cardioform Septal Occluder, Gore Cardioform Asd Occluder |
| Cardiovascular Systems INC. | $170.38 | 2022-2023 | Diamondback Coronary |
| Medtronic Vascular, INC. | $140.24 | 2020 | |
| Penumbra, INC. | $133.38 | 2022 | |
| Teleflex LLC | $104.85 | 2023 | Guideliner |
| Novo Nordisk INC | $97.15 | 2023-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $46.80 | 2025 | |
| Merck Sharp & Dohme LLC | $44.49 | 2023-2025 | Verquvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.73 | 2019 | |
| Biosense Webster, INC. | $39.43 | 2025 | Carto 3 |
| Amgen INC. | $31.20 | 2024-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $28.87 | 2025 | Camzyos |
| Spectrawave, INC | $27.51 | 2025 | Starlight Imaging Catheter, Hypervue Imaging System |
| Kiniksa Pharmaceuticals International, Plc | $18.44 | 2024 | Arcalyst |
| Philips North America LLC | $16.84 | 2024 | (5044) Mcot |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4.21 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yashasvi Chugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.